Pomegra
Arintra's $25M Series B led by Define Ventures brings total funding to $51M as its autonomous coding platform clears $5B in annualized health system claims.
- Arintra closed a $25M Series B on August 24, 2026, led by Define Ventures, with new strategic capital from Yale New Haven Ventures and Endeavor Ventures.
- The platform now processes more than $5 billion in annualized claim value across clients including UC Davis Health, Rochester Regional Health, and Mercyhealth.
- The round follows a $21M Series A closed just twelve months prior, putting total capital raised at $51 million; valuation was not disclosed.
Lead
Arintra, an Austin-based GenAI startup that automates medical billing code assignment, closed a $25 million Series B on August 24, 2026, led by Define Ventures. The round added strategic backers Yale New Haven Ventures and Endeavor Ventures alongside returning investors Peak XV Partners, Y Combinator, Counterpart Ventures, Ten13 Capital, and Spider Capital. The company's platform now moves more than $5 billion in annual claim value through its coding engine on behalf of U.S. health systems.
What Does Arintra Actually Do?
Arintra pairs large language models with clinical knowledge graphs to read unstructured patient charts and assign specialty-specific billing codes - CPT, ICD-10, HCC, and HCPCS - without human intervention at the line level. The platform covers more than 23 specialties, spanning ambulatory, emergency, diagnostic, and inpatient settings. In December 2024, the autonomous coding solution became available through the Epic App Orchard Toolbox, giving Epic-integrated health systems a direct procurement pathway.
Named customers include UC Davis Health, Mercyhealth, Meritus Health, Rochester Regional Health, Reid Health, and Mercy Medical Center. The $5 billion annualized figure is a throughput metric, not revenue. It represents the aggregate claim value the system codes on behalf of clients, a number that matters because coding errors affect reimbursement rates in both directions - undercoding leaves money on the table, overcoding creates compliance exposure.
Why Is Define Ventures Leading This Round?
Define Ventures concentrates exclusively on healthcare, which matters for enterprise sales cycles. Healthcare-specialist investors typically bring payer and provider introductions that generalist firms cannot replicate, and medical coding is a domain where clinical credibility shortens the time from demo to signed contract. Peak XV Partners, which led the $21 million Series A in August 2025, returned for this round - a signal of internal confidence in the growth trajectory between rounds.
The twelve-month interval between Series A and Series B is compressed relative to standard VC timelines, suggesting either strong revenue growth or a deliberate decision to accelerate hiring and market expansion before a competitor consolidates enterprise accounts. The company has not disclosed its valuation.
Platform Scale and the Coding Problem
Medical coding is one of U.S. healthcare's most persistent administrative drags. Health systems employ tens of thousands of human coders, and error rates affect both revenue integrity and audit risk. Rule-based automation has been attempted for decades, but earlier tools struggled with the complexity of clinical language and the variation across specialties.
Arintra's founders - CEO Nitesh Shroff and CTO Preeti Bhargava, both machine-learning PhDs - built the platform from an AI-native architecture rather than layering models onto legacy coding software. That design choice is what allows the system to handle 23-plus specialties rather than one or two highly standardized ones, a meaningful differentiator for hospital systems running diverse service lines under a single procurement contract.
The Epic integration adds distribution weight that most clinical AI startups spend years trying to build. Epic holds a commanding position among large health systems, and Toolbox placement reduces the friction that typically stalls clinical AI adoption at the IT governance layer.
Outlook
Arintra now carries $51 million in total funding, a defined investor base spanning healthcare-focused and generalist VC, and an established distribution channel through one of the dominant EHR platforms. The $5 billion annualized throughput metric gives prospective clients a concrete benchmark, even as the company's financial performance remains private.
The central test over the next 12 to 18 months is whether autonomous coding at scale reduces error rates sufficiently to justify the switch cost relative to hybrid human-AI models. Health systems are under sustained margin pressure - a dynamic that creates urgency to automate but also makes procurement committees conservative about replacing mid-cycle workflow dependencies. Arintra's customer list suggests enterprise traction; the pace of expansion from that base will determine whether this round buys growth or runway.
